Scarica l'app Stockscreener
56.93
0.14%
0.08
Dopo l'orario di chiusura:
56.93
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
Investigation launched into Travere Therapeutics officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm - TradingView
Travere Therapeutics (TVTX) Secures FILSPARI Patent Extension, Is The Stock A Bargain? - Simply Wall Street
RTRX5376243 Bond Profile: Coupon and Redemption - TradingView
TVTX Maintained by Guggenheim -- Price Target Raised to $89.00 - GuruFocus
Travere Therapeutics Is Maintained at Buy by Guggenheim - moomoo.com
Guggenheim raises Travere Therapeutics stock price target on patent By Investing.com - Investing.com Canada
Understanding the Setup: (TVTX) and Scalable Risk - news.stocktradersdaily.com
Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI - marketscreener.com
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis - BioSpace
Travere receives patent allowance for FILSPARI use in FSGS - Investing.com
Travere TherapeuticsReceives USPTO Notice Of Allowance For Filspari Patent In FSGS - TradingView
TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside - Stocktwits
Travere Therapeutics, Inc. (TVTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Travere Therapeutics (TVTX) Sets CEO Handover For December 2026 - Yahoo Finance
Why Everyone Is Watching Travere Therapeutics (TVTX) Today - Simply Wall Street
Travere Therapeutics appoints new CEO Bradley Campbell - The Globe and Mail
Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today - Yahoo Finance
TVTX Reiterated by Wedbush -- Price Target Maintained at $76.00 - GuruFocus
Travere Therapeutics Names Bradley Campbell CEO - Contract Pharma
Wedbush reiterates Outperform rating on Travere Therapeutics, $76 price target - TradingView
HC Wainwright & Co. reiterates Buy rating on Travere Therapeutics, $67 price target - TradingView
TVTX Looks 64.1% Overvalued on GF Value™ - GuruFocus
Travere Therapeutics Announces Planned Chief Executive Officer Transition - BioSpace
Travere Therapeutics stock falls amid CEO transition news By Investing.com - Investing.com Nigeria
Travere Therapeutics Names Bradley Campbell CEO Effective December 1, 2026 - Minichart
Travere Therapeutics stock falls amid CEO transition news - Investing.com
Travere Therapeutics CEO Eric Dube to step down in December By Investing.com - Investing.com Australia
Travere Therapeutics President and CEO Eric Dube Plans to Step Down - marketscreener.com
Travere Therapeutics, Inc. Announces CEO Changes, Effective December 1, 2026 - marketscreener.com
Travere Therapeutics (NASDAQ:TVTX) Passes Minervini Trend Template With High-Growth Momentum - ChartMill
Travere Therapeutics CFO Cline Christopher R. Executes Options and Sells Shares on September 15, 2026 - Kalkine Media
Travere Therapeutics Insider Sold Shares Worth $2,785,021, According to a Recent SEC Filing - marketscreener.com
Travere Therapeutics Insider Sold Shares Worth $2,337,695, According to a Recent SEC Filing - marketscreener.com
Travere Therapeutics Insider Sold Shares Worth $25,390,729, According to a Recent SEC Filing - marketscreener.com
Travere Therapeutics Insider Sold Shares Worth $13,135,397, According to a Recent SEC Filing - marketscreener.com
Travere therapeutics chief research officer William Rote sells $13.1m in stock - Investing.com Canada
Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock - Investing.com Australia
Travere Therapeutics CLO Elizabeth Reed sells $2.34m in stock By Investing.com - Investing.com Australia
Travere Therapeutics CFO Cline sells $3.1m in company stock By Investing.com - Investing.com Australia
Travere Therapeutics CFO Cline sells $3.1m in company stock - Investing.com
Travere therapeutics CEO Eric Dube sells $25.4m in shares By Investing.com - Investing.com Canada
Jula Inrig Sells 44,674 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) EVP Sells $10,955,439.31 in Stock - MarketBeat
Travere Therapeutics SVP sells $335k in stock - Investing.com
Travere Therapeutics SVP sells $335k in stock By Investing.com - Investing.com Canada
Travere (TVTX) R&D boss sells stock under 10b5-1 plan—how big was the trade? - Stock Titan
Travere Therapeutics (TVTX) legal chief sells 37,500 shares under trading plan - Stock Titan
Travere Therapeutics (TVTX) chief accounting officer sells 5,375 shares under preset plan - Stock Titan
Travere Therapeutics (TVTX) research chief unloads shares under a preset plan, with the sale size now disclosed - Stock Titan
Planned $6.9M stock sale in Travere (NASDAQ: TVTX) - Stock Titan
Travere (NASDAQ: TVTX) insider plans more stock sales after multi-million plan trades - Stock Titan
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum - Yahoo Finance
Travere Therapeutics, Inc.Common Stock (Nasdaq:TVTX) Price Chart - The Chronicle-Journal
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):